United Heart & Vascular Clinic - Nasseff Specialty Center (MHI East)
Welcome,         Profile    Billing    Logout  
 5 Trials 
5 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bank, Alan J
SWAN, NCT04971993: Step and Walking Pattern From Cardiac Monitor Study

Terminated
N/A
40
US
Wearable Cardiac Monitor
Boston Scientific Corporation
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Insertable Cardiac Monitor
10/23
10/23
Brown, Christopher
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
RESTORE, NCT04803214: ReActiv8 Stimulation Therapy vs Optimal Medical Management: A Randomized Evaluation

Active, not recruiting
N/A
203
US
ReActiv8
Mainstay Medical
Chronic Low-back Pain
09/24
01/26

Download Options